The efficacy outcomes in non-small cell lung cancer patients treated with PD axis inhibitor agents - a population-based study of the Vojvodina region

• Main Authors: Nensi Lalić (Author), Marko Bojović (Author), Daliborka Bursać (Author), Darijo Bokan (Author), Vesna Čeriman Krstić (Author), Ivan Kuhajda (Author), Biljana Parapid (Author), Sanja Tomić (Author), Aleksandar Šipka (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: By 2021, the FDA approved the use of the drugs pembrolizumab and atezolizumab in the first-line treatment of patients with high positivity of programmed death ligand-1 (PD-L1) in locally advanced and metastatic non-small-cell-lung cancer (NSCLC). This approval was the result of statistic...